TTrialPathMatch Me to Trials
← Back to trials
RecruitingMetastatic Non-small Cell Lung Cancer With MTAP Deletion

A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion

Eligible age

18+ yrs

Accepts

All genders

Locations

26 states

Healthy volunteers

No

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

The purpose of this study is to compare the clinical benefit of the combination of Navlimetostat (BMS-986504) (a selective MTA-cooperative inhibitor of PRMT5) plus pembrolizumab and chemotherapy versus placebo plus pembrolizumab and chemotherapy in first-line metastatic non-small cell lung cancer participants with homozygous MTAP deletion

Sponsor: Bristol-Myers Squibb

You may qualify if…

  • ✓ Participants must have Metastatic (Stage IV or recurrent) non-small cell lung cancer (NSCLC) (as defined by the American Joint Committee on Cancer, Ninth Edition) with no prior systemic anti-cancer therapy for metastatic disease.
  • ✓ Participants must have histologically confirmed diagnosis of NSCLC and homozygous methylthioadenosine phosphorylase (MTAP) deletion or MTAP loss.
  • ✓ Participants must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.
  • ✓ Participants must have at least 1 measurable lesion as per RECIST v1.1.

You may not qualify if…

  • ✕ Nonsquamous participants must not have documented targetable oncogenic mutation or actionable genetic alterations (AGAs) for which there is a standard of care (SoC) available as first-line (1L) therapy.
  • ✕ Participants must not have symptomatic brain metastases or spinal cord compression.
  • ✕ Participants must not have any prior systemic therapy (chemotherapy, immunotherapy, targeted therapy, or biological therapy) for metastatic non-small cell lung cancer (mNSCLC).
  • ✕ Note: One cycle of SoC treatment prior to randomization will be allowed for participants who require immediate treatment if clinically indicated.
  • ✕ Participants must not have any known or suspected impairment of gastrointestinal function that may prohibit the ability to absorb or swallow an oral medication without chewing or crushing.
  • ✕ Other protocol-defined Inclusion/Exclusion criteria apply.

Where it's recruiting

Alaska

Anchorage

Arizona

Phoenix · Tucson

Arkansas

Springdale

California

Los Alamitos · Los Angeles

Delaware

Newark

Florida

Fort Lauderdale · Jacksonville · St. Petersburg · Tampa

Idaho

Boise

Illinois

Decatur

Kentucky

Lexington

Maine

Scarborough

Michigan

Ann Arbor · Detroit · Traverse City

Source: ClinicalTrials.gov · NCT07063745 · last updated 2026-11-13

A Study to Compare the Combination of Navlimetostat (BMS-986504) With · TrialPath